4D Molecular Therapeutics, Inc. Operating Lease Liability
4D Molecular Therapeutics, Inc. (FDMT) had Operating Lease Liability of $19.63 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-08-13
- 2026-06-30: Operating Lease, Liability $19.63M.
- 2026-03-31: Operating Lease, Liability $20.54M.
- 2025-12-31: Operating Lease, Liability $21.41M.
- 2025-09-30: Operating Lease, Liability $22.26M.
| Period end | Operating Lease, Liability |
|---|---|
| 2026-06-30 | $19.63M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $20.54M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $21.41M 10-K · filed 2026-03-18 |
| 2025-09-30 | $22.26M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $23.08M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $23.85M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $24.61M 10-K · filed 2025-02-28 |
| 2024-09-30 | $24.83M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $13.66M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $14.17M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $14.67M 10-K · filed 2024-02-29 |
| 2023-09-30 | $15.16M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $15.63M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $15.68M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $16.12M 10-K · filed 2023-03-15 |
| 2022-09-30 | $16.55M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $17.00M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $16.82M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $16.45M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |